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5 studies were selected that reported appropriate data to assess test-retest reliability 
and 26 studies were selected which reported alpha coefﬁcient scores to determine the 
internal consistency of the HADS. Factor analysis studies revealed consistent bi-
dimensional or tripartite models, with few exceptions. Just one study of ﬁve evaluated 
fulﬁlled he criteria for good test-retest reliability. However, most of the studies report-
ing alpha revealed an acceptable level of internal consistency reliability. CONCLU-
SIONS: Based on the studies in the review, the ﬁndings suggest that the HADS may 
be an effective screening tool in an alcohol dependent population, though there is a 
caveat to this. The test-retest characteristics appear unsatisfactory in the studies 
selected. Notwithstanding the test-retest reliability characteristics, factor structure and 
internal consistency evidence would suggest the instrument to be suitable for use in 
an alcohol-dependent population.
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CONCORDANCE OF COMPUTERIZED SELF-REPORT MEASURES OF 
DSM-IV-TR MOOD AND ANXIETY DISORDERS COMPARED TO GOLD 
STANDARD CLINICAL ASSESSMENTS IN PRIMAY CARE
Kessler RC1, Farley PA2, Gruber M1, Harshaw Q2, Jewell MA2, Sampson N1, 
Shillington AC2
1Harvard Medical School, Boston, MA, USA, 2EPI-Q Inc, Oak Brook, IL, USA
OBJECTIVES: Substantial numbers of patients presenting to primary care suffer 
unrecognized disorders of mood or anxiety, potentially complicating treatment and 
outcome. The objective of this study was to evaluate the validity of an electronic 
screening instrument based upon the World Health Organization’s Composite Inter-
national Diagnostic Interview (WHO CIDI) and DSM-IV-TR designed for use in 
primary care. This is a fully-structured computerized instrument designed to screen 
for bipolar disorder (BPD), generalized anxiety disorder (GAD), panic disorder (PD) 
and major depressive episodes (MDE) in primary care patients. METHODS: A pre-
liminary version of the instrument was piloted in individuals with known disease. 
Following cognitive interviews with subjects, it was reﬁned and tested in 3058 respon-
dents from 29 primary care physician ofﬁces across the US. Sub-samples were selected 
to receive a reappraisal interview (n = 206), over-sampling on those screening positive 
for either the disorders. To assess validity each completed a “gold-standard” Struc-
tured Clinical Interview for DSM (SCID) administered via phone by trained clinicians. 
RESULTS: Individual-level concordance was good between the screener diagnoses and 
the SCID assessments. Area under the receiver operating characteristic curve (AUC), 
a measure of classiﬁcation accuracy not inﬂuenced by disorder prevalence) demon-
strated substantial agreement for MDE (AUC = 0.85). BPD initially demonstrated 
fair-moderate agreement (AUC = .78), but this was improved to the “substantial” 
range (AUC = 0.86) with the enhancement of history of lifetime mania in the SCID 
interview. PD and GAD both demonstrated fair-moderate agreement (AUC = 0.79 
and AUC = 0.67; respectively). CONCLUSIONS: The results demonstrate that the 
CIDI-based computerized screening instrument can be used to identify the vast major-
ity of patients with a high likelihood of mood and anxiety disorders treated in the 
primary care setting.
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EVALUATION OF PSYCHOMETRIC EQUIVALENCE BETWEEN 
INTERACTIVE VOICE-RESPONSE (IVR) AND PAPER VERSIONS OF 
DAILY ASSESSMENT SCALE FOR ANXIETY (DAS-A)
Mundt J1, Hassan M2, Lappalainen J2, Morlock R3
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OBJECTIVES: The DAS-A is an 8-item patient-reported instrument designed to detect 
daily changes of anxiety symptoms in patients with Generalized Anxiety Disorder 
(GAD) during the ﬁrst week of treatment. This study compared the psychometric and 
measurement properties of an IVR version of the DAS-A with the original paper 
version. METHODS: Adult patients with GAD were enrolled at the screening visit of 
a clinical trial. Treatment randomization occurred at day 0. Patients were scheduled 
to complete the IVR DAS-A from day −6 through day 7. Paper-and-pencil DAS-A 
forms were completed by selected patients during clinic visits on days 0, 4 and 7. 
Psychometric properties of both DAS-A forms were compared with respect to internal 
scale consistency (Chronbach’s alpha), item reliability (intraclass correlation coefﬁ-
cient; ICC), and mean score equivalence when both formats were administered within 
24 hours of each other (paired t-tests). RESULTS: A total of 2804 IVR DAS-A assess-
ments and 119 paper DAS-A forms were completed. In 62 instances both formats 
were completed within 24 hours of one another. Cronbach’s alpha across all IVR 
DAS-A administrations was 0.85; the mean ICC was 0.84 (95% CI = 0.83–0.85). 
Cronbach’s alpha across all paper DAS-A administrations was 0.90; the mean ICC 
was 0.89 (95% CI = 0.86–0.92). The mean (± SD) IVR and paper DAS-A total scores 
were 58.97 (± 20.09) and 60.91 (± 21.00), respectively; this difference was not statisti-
cally signiﬁcant, t = 1.89, p. = 0.06. The correlation between the DAS-A total scores 
was 0.90, p. < 0.001. Comparisons between DAS-A formats at an item-by-item level 
found signiﬁcant inter-method correlations (range 0.59 to 0.79); one item identiﬁed a 
potentially signiﬁcant difference in mean score, t = 2.05, p. = 0.04, but likely reﬂects 
Type I error inﬂation. CONCLUSIONS: This analysis supports the equivalence of the 
IVR and paper DAS-A formats for measuring daily changes of anxiety symptoms in 
patients with GAD.
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INTENSIVE COGNITIVE INTERVIEWING WITH PATIENTS DIAGNOSED 
WITH SCHIZOPHRENIA AND THE REFINEMENT OF THE CLEAR 
THINKING SCALE (CTS)
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OBJECTIVES: Intensive cognitive interviews are valuable in the reﬁnement of patient 
reported outcome (PRO) instruments and can identify how patients perceive the 
meaning of questions, how they develop and justify their responses and can allow the 
researcher to test face validity and burden of the instrument. We conducted intensive 
cognitive interviews with outpatients diagnosed with schizophrenia to reﬁne the clear 
thinking scale (CTS)—a recently validated PRO instrument that assesses patient prefer-
ences and functioning across four sub-domains (staying organized; making sense of 
the world; feeling clear headed; and expressing thoughts and feelings). METHODS: 
Intensive cognitive interviews were conducted by an experienced interviewer at various 
facilities associated with Johns Hopkins. Following the consenting process, partici-
pants completed the preferences (5 items) and functioning (28 items) components of 
the CTS. Concurrent and retrospective verbal probing was utilized to assess the 
respondent level of understanding and burden. All interviews were recorded, tran-
scribed and analyzed using phenomenological qualitative methods. RESULTS: A total 
of 20 patients with a primary diagnosis of diagnosis of schizophrenia or schizoaffective 
disorder participated in the study. While respondents regularly got off topic and often 
lacked conﬁdence in their answers, we found a relatively consistent interpretation of 
items across respondents. We also identiﬁed several approaches to improving the CTS 
scale, including: 1) simplifying items and avoiding compounded items; 2) repeating 
the time frame (i.e., in the past week) before every question; 3) supporting response 
variables with numbers/details; 4) using rankings rather than ratings to elicit patient 
preferences; 5) avoiding items that might have a literal interpretation; 6) measuring 
functioning prior to measuring preferences; and 7). having an example question for 
both functioning and preferences questions. CONCLUSIONS: Despite its difﬁculties, 
intensive cognitive interviewing among patients diagnosed with schizophrenia pro-
vided valuable information for the reﬁnement of the CTS and other future PRO scales.
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EFFECT OF EQUIVALENT AND NON-EQUIVALENT SUBSTITUTION OF 
PRESCRIBED DRUGS FOR DEPRESSION AND ANXIETY DISORDERS ON 
PATIENTS’ TREATMENT ADHERENCE AND PERCEPTION
LaPensee K1, Carson R1, Werner P1, Sexton CC2, Gelhorn H2, Stankus A3, Erder H1
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OBJECTIVES: To assess the impact of “equivalent substitution” (true generic of the 
prescribed drug) or “non-equivalent substitution” (switch to another agent, brand or 
generic) on perceptions, attitudes, and treatment adherence in patients with and 
without depression and anxiety disorder. METHODS: Over 10,000 randomly-selected 
US respondents from the 2007 National Health and Wellness Survey (NWHS) com-
pleted a self-administered, internet-based survey. The subpopulation of 2360 self-
identiﬁed anxious/depressed respondents was supplemented with 5539 re-contacted 
self-identiﬁed anxious/depressed responders from the 2006/2007 NWHS. Responses 
from non-anxious/depressed patients were compared to those of self-identiﬁed 
anxious/depressed patients using t-tests, ANOVA, and multiple linear and logistic 
regressions. Comparisons were also made between anxious/depressed subgroups. 
RESULTS: A total of 52% of non-anxious/depressed patients experienced therapeutic 
substitution; 50% reported equivalent and 18% to non-equivalent substitutions (dif-
ferent brand—10%, generic of another agent—8%). 51% of the non-anxious/
depressed and 71.5% of the anxious/depressed patients have experienced switching. 
More anxious/depressed patients found required step therapy unacceptable (P < 0.001; 
many tried to change health plans for this reason.77% of non-anxious/depressed and 
81% of anxious/depressed patients considered equivalent substitution (an equivalent 
generic) acceptable, but only about half in both groups thought that non-equivalent 
substitution was acceptable. Substitution affected attitudes and treatment adherence 
signiﬁcantly more in anxious/depressed vs. non-anxious/depressed patients. Impor-
tantly, anxious/depressed patients subjected to non-equivalent substitution reported 
signiﬁcantly lower treatment adherence than those who were not (P < 0.001). Switch-
ing to a non-equivalent generic also reduced adherence more than switching to an 
equivalent generic (P < 0.0001) in this population. CONCLUSIONS: About half of 
all respondents found required step therapy unacceptable. Anxious/depressed patients 
reported signiﬁcant deterioration of treatment adherence and treatment-related atti-
tudes following equivalent, and especially non-equivalent substitution. Substitution of 
prescribed drugs for depression or anxiety disorders negatively affected self-reported 
treatment adherence in the treated population, which may impact treatment 
outcomes.
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FUNCTIONAL IMPAIRMENT IN CHILDREN AND ADOLESCENTS  
WITH DEPRESSION
Nagar S1, Aparasu RR2, Chen H2, Sherer J2
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TX, USA
OBJECTIVES: This study examined the extent of functional impairment in children 
and adolescents aged 5 to 17 years with depression based on 2005–2006 Medical 
Expenditure Panel Survey (MEPS) data. METHODS: This study involved retrospective 
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cross-sectional analysis of 2005–2006 MEPS data involving children. Functional 
impairment was ascertained using the mean summated scores (range 0–52) of the 
parent-reported Columbia Impairment scale (CIS). Psychometric properties of the CIS 
were evaluated for the study sample. The Wilson and Cleary Model was used to 
examine the factors associated with functional impairment in children and adolescents. 
The primary independent variable of interest was depression. Multivariate linear 
regression involving the SURVEYREG procedure was applied to the study sample to 
identify the predictors of functional impairment in children and adolescents. 
RESULTS: Analysis of the CIS revealed that Cronbach’s alpha of the parent-reported 
CIS was 0.90 with item-to-total correlations ranging from 0.51 to 0.77. The mean 
summated CIS score of children and adolescents with depression (CIS, 19.88) was 
higher than those without depression (CIS, 6.09). Multivariate linear regression 
revealed that the interaction between age and depression was signiﬁcant and therefore 
stratiﬁed regression analysis was performed by age. In both age groups, the diagnosis 
of depression was strongly associated with functional impairment (+7 units in ages 
5–11 years, +11 units in ages 12–17 years). The presence of developmental, respiratory 
tract, attention deﬁcit, and anxiety disorders also increased functional impairment in 
children and adolescents. Family factors such as parents’ psychiatric illness, their 
highest education level and family living arrangement further contributed to impair-
ment in children. CONCLUSIONS: Functional impairment is signiﬁcant in pediatric 
depression and understanding of personal and family factors can play an important 
role in the assessment, management and treatment of depression.
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THE RELIABILITY AND VALIDITY OF THE CLEAR THINKING SCALE 
(CTS) AMONG PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
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OBJECTIVES: Previous research has demonstrated that clear thinking is relevant to 
patients diagnosed with schizophrenia. We tested the reliability and validity of an 
experimental clear thinking scale (CTS) among a sample of outpatients diagnosed with 
schizophrenia. The CTS measures functioning across four sub-domains: staying orga-
nized (SO); making sense of the world (MS); feeling clear headed (CH); and expressing 
thoughts and feelings (TF). METHODS: Following item generation and reduction, 
cognitive interview were used to reﬁne the survey instrument. The scale was then 
ﬁelded to a sample of outpatients diagnosed with schizophrenia. The reliability and 
validity of the CTS and its four sub-domains was assessed using the Cronbach’s alpha 
and comparison to the Clyde mood scale (CMS) construct of “clear thinking”. 
RESULTS: Cognitive interviews (n = 12) identiﬁed several items that patients had 
difﬁculty understanding, which were subsequently removed or reworded. We also 
found that all items needed to be unidirectional and measuring deﬁcits (i.e., while clear 
thinking is a positive construct, patients related to it best in its absence). A sample of 
51 outpatients diagnosed with schizophrenia (66% male; average age = 49 y; average 
time since diagnosis = 22 y) completed the survey (only one respondent was unable 
to complete the survey. Cronbach’s alphas for all constructs were good: .77 (SO), .79 
(MS) .79 (CH), and .83 (TF), and was excellent for the overall scale (.93). All con-
structs were positively correlated with CMS clear thinking construct, which had a 
Cronbach’s alpha of .8, but these correlations were signiﬁcant only for TF (p = 0.002) 
and the overall scale (p = 0.02). CONCLUSIONS: Findings indicate that clear thinking 
can be reliably and validly described over four domains that are relevant to patients 
diagnosed with schizophrenia. Future research will focus on further reﬁning the CTS, 
comparing it with other scales of functioning and disease symptoms and assessing its 
sensitivity to changes.
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ANALYSIS OF ADOLESCENT PATIENTS WITH NON-DEPRESSIVE 
NEUROSES IN COMPARISON TO THE GENERAL INPATIENT GROUP
Houlette B
University of Louisville, Louisville, KY, USA
OBJECTIVES: To analyze a variety of variables for DRG 427, non-depressive neuro-
ses, in comparison to the control group to determine any trends or discrepancies. 
METHODS: The data were taken from the Kids’ Inpatient Database (KID) from year 
2007. This database describes hospital inpatient stays for children. To create a control 
group for comparison, a random sample of 8201 patients with DRG codes other than 
427 was taken. The control group combined with the experimental group, DRG code 
427, gives a total of 16,402 entries to examine. RESULTS: The diagnosis of non-
depressive neuroses was found to be much more prevalent in females than males. 
While the general inpatient group was only 47% female, the speciﬁc DRG group was 
57% female. Kernel density estimations revealed that the speciﬁc DRG group on 
average had shorter lengths of stay and lower total charges than the general inpatient 
group. A logistic regression performed showed that patient demographics and severity 
levels are all signiﬁcant in predicting whether a patient will be classiﬁed as general 
inpatient group or speciﬁc DRG group. Linear regressions also showed that both the 
APRDRG and Disease Staging Resource Demand severity indices are signiﬁcant in 
predicting a patient’s total charges and length of stay. A linear regression using the 
top 10 diagnosis and procedure codes to predict length of stay showed that these 
variables predict very little of the variability. CONCLUSIONS: From the initial sta-
tistical analyses, it is evident that the experimental group had more females than males 
and on average showed shorter lengths of stay and charges than the control group. 
Also, severity levels proved to be consistently signiﬁcant in predicting the control, 
length of stay, and total charges while patient demographics and diagnosis and pro-
cedure codes were only signiﬁcant in some models.
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STATISTICAL ANALYSIS OF DIAGNOSIS RELATED GROUP 521: 
ALCOHOL/DRUG ABUSE OR DEPENDENCE WITH COMPLICATIONS 
AND COMORBIDITIES
Gullett MJ
University of Louisville, Louisville, KY, USA
OBJECTIVES: To conduct exploratory data analysis on DRG 521: alcohol/drug abuse 
or dependence with complications and comorbidities. Comparing DRG 521 to a 
control group will provide insights into statistical trends relating to this particular 
diagnosis. METHODS: The data used for this statistical analysis were obtained from 
The Kids’ Inpatient Database (KID) from 2007. KID is a national database containing 
information on hospital inpatient stays for children twenty years old and younger. In 
this database, there are 1,447 cases of DRG 521. For comparison purposes, a random 
sample equal in size was drawn from all DRG codes other than DRG 521. The statisti-
cal software, SAS, is used to analyze this data set. RESULTS: Initial statistical analyses 
have shown a greater proportion of whites in the experimental group (DRG 521), 
72%, compared to the control group with 61%. The overwhelming majority of the 
experimental group is in the higher age range of ﬁfteen to twenty years old, compared 
to the control group which has a uniform distribution across all ages. In addition, the 
experimental group contains a higher proportion of males, 55.8%, compared to the 
control group, 52%. CONCLUSIONS: Previous research has indicated that when 
individuals have comorbid conditions including drug/alcohol dependence and mental 
illnesses, males are more likely to be treated and seek treatment for substance depen-
dence whereas females are more likely to seek treatment for mental illnesses. This 
information could explain why more males are present in the experimental 
group,compared to the control group. In addition, adolescence and young adults are 
more likely to engage in risky behavior, which would explain the concentration of 
older individuals in the experimental group.
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THE ASSOCIATION BETWEEN TYPE OF ANTIPSYCHOTIC AND RATES 
OF HOSPITALIZATION AMONG MEDICARE BENEFICIARIES
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OBJECTIVES: The objective of this study is to compare rates of hospitalization among 
patients receiving different classes of antipsychotics (SGAs, FGAs, both, or none) in 
a large, all-ages sample of both institutionalized and noninstutionalized Medicare 
beneﬁciaries. METHODS: We examined the 2005 Medicare Current Beneﬁciary 
Survey (MCBS) Cost and Use ﬁle Prescription Drug Event (PDE) module for 11,236 
survey participants. Antipsychotic utilization was characterized in terms of class: FGA 
(chlorpromazine, ﬂuphenazine, haloperidol, loxapine, perphenazine, thiothixene, thio-
ridazine, and triﬂuoperazine) or SGA (aripiprazole, clozapine, olanzapine, quetiapine, 
risperidone, and ziprasidone). Hospitalization was deﬁned in terms of whether a 
Medicare beneﬁciary was admitted to the hospital for any reason in 2005, and the 
number of hospital visits. RESULTS: About 3.5% of Medicare beneﬁciaries (1.3 
million) ﬁlled one or more prescriptions for an antipsychotic medication in 2005. 
Rates of all-cause hospitalization among Medicare beneﬁciaries were signiﬁcantly 
higher for SGA users than for FGA users: 38.9% of those who used only SGAs com-
pared to 31.0% of FGA-only users. Patients prescribed both FGAs and SGAs had the 
highest rate of hospitalization (60.7%), compared to 21.3% of nonusers. Controlling 
for demographic, socioeconomic, health, and disability variables, SGA users were over 
twice as likely (odds ratio, 2.2; 95% CI, 1.17–2.9), and combination users were over 
six times as likely (odds ratio, 6.3; 95% CI, 2.4–16.2) as nonusers to be hospitalized. 
The odds of FGA users being hospitalized were not signiﬁcantly different from nonus-
ers (odds ratio, 1.4; 95% CI, 0.7–2.8). CONCLUSIONS: This analysis offers provoca-
tive, but by no means conclusive evidence that SGAs as a class are not necessarily 
superior to FGAs in mitigating patient’s use of hospital services, Systematic analysis 
of this relationship with a longitudinal sample of Medicare beneﬁciaries is 
warranted.
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ANTIPSYCHOTIC USE IN SENIORS: AN ANALYSIS FOCUSING ON 
DRUG CLAIMS FROM 2001 TO 2007
Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada
OBJECTIVES: The majority of antipsychotic use in the elderly is to treat behavioural 
and psychological symptoms of dementia. New information on the safety of antipsy-
chotics in the elderly was released between 2000 and 2005. This analysis provides 
insight into antipsychotic use among seniors during this time period. METHODS: 
Claims level data from the National Prescription Drug Utilization Information System 
(NPDUIS) Database were analyzed for seniors on public drug programs in six Cana-
dian provinces between 2001–2002 and 2006–2007. This analysis looked at trends in 
antipsychotic use, including use by age and sex. Additional analyses focused on atypi-
